PROTACs that target Bruton's tyrosine kinase have shown great response rates in B-cell cancers, and molecular glues that target Ikaros family proteins (IKZF1/3) are still helping people with blood cancers. This evidence concerns the gene IKZF1 and hematopoietic and lymphoid system neoplasm.